5.48
-0.225(-3.95%)
Currency In USD
| Previous Close | 5.7 |
| Open | 5.8 |
| Day High | 5.85 |
| Day Low | 5.39 |
| 52-Week High | 11.2 |
| 52-Week Low | 2.92 |
| Volume | 80,262 |
| Average Volume | 89,080 |
| Market Cap | 35.33M |
| PE | -0.74 |
| EPS | -7.36 |
| Moving Average 50 Days | 4.26 |
| Moving Average 200 Days | 5.89 |
| Change | -0.23 |
If you invested $1000 in Kala Pharmaceuticals, Inc. (KALA) since IPO date, it would be worth $5.92 as of July 16, 2025 at a share price of $5.475. Whereas If you bought $1000 worth of Kala Pharmaceuticals, Inc. (KALA) shares 5 years ago, it would be worth $9.98 as of July 16, 2025 at a share price of $5.475.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 202
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
GlobeNewswire Inc.
Jul 07, 2025 12:00 PM GMT
ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the ey
KALA BIO to Present at Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye